<DOC>
	<DOCNO>NCT01358409</DOCNO>
	<brief_summary>Within large number patient obesity , crucial determine great risk development chronic heart disease . The investigator previous study suggest excessive accumulation fat heart cell precede development obesity-related pathology may serve biomarker heart disease high-risk population . Until , evaluation fat human heart possible postmortem biopsy . The investigator novel magnetic resonance spectroscopy technique enable quantification intracellular lipid content non-invasively repeatedly humans vivo . It could use well screen treat obese patient risk development metabolic disease . The investigator hypothesize obese human elevate myocardial triglyceride , treatment Nebivolol reduce myocardial fat improve heart function .</brief_summary>
	<brief_title>Regression Myocardial Steatosis Nebivolol</brief_title>
	<detailed_description>Background : Epidemiological data provide abundant evidence show obesity major risk factor cardiovascular morbidity mortality , although exact mechanism remain incompletely understood . Traditionally , obesity think indirectly increase cardiovascular risk mean intermediary effect ; obesity increase risk hypertension , dyslipidemia , diabetes mellitus , thereby increase one 's overall risk cardiovascular disease . In contrast traditional view , grow body research group others advance novel hypothesis ectopic myocardial fat deposition directly damage heart . Lipid deposition overload myocardium , term `` cardiac steatosis '' , directly toxic cardiac myocytes . Deposition lipid droplet non-adipocytes ( Steatosis ) : Normally , triglyceride body store adipose tissue little lipid accumulation non-adipocytes ( e.g . parenchymal cell liver , pancreas , muscle ) due balance fatty acid uptake oxidation . When mechanism defective , fat accumulate non-adipocytes . This abnormal retention lipid within non-adipose tissue heart , liver , pancrease , skeletal muscle know `` steatosis '' reflect impairment normal synthesis elimination triglyceride . This first demonstrate pancreatic β-cells obese Zucker rat , genetic model obesity . The intracellular accumulation long chain free fatty acid ( FFA ) hypothesize engage adverse signal cascade conversion Ceramide stimulate inducible nitric oxide synthase ( iNOS ) , eventually leading apoptosis . Progressive apoptosis lipid-laden pancreatic β-cells time eventually lead insulin deficiency . A combination β-cell failure insulin resistance produce diabetes animal model . More importantly , pancreatic steatosis pre-diabetic Zucker rat accompany metabolic abnormality show effectively reverse PPAR-Ƴ antagonist , Troglitazone . The next logical step ask similar mechanism lead deposition lipid droplet within cardiomyocytes . Indeed , prediabetic obese Zucker rat deposit fat cardiomyocytes ; whereas , lean rat deposit fat cardiomyocytes . Furthermore , obese Zucker rat progressive leave ventricular systolic dysfunction , presumably due excessive lipid deposition toxicity , dysfunction occur onset frank diabetes . In human study , MR spectroscopy allow non-invasive evaluation number size lipid droplet cardiomyocytes . Similar rodent study , group demonstrate strong linear relationship triglyceride deposition myocardium LV concentricity function . Nebivolol role myocardial steatosis regression : Nebivolol ( Bystolic® Forest/Mylan ) various mode action exquisite ability regress cardiac steatosis many different level . We propose novel mechanism Nebivolol action result reduction myocardial steatosis . Specific aim : This investigation study whether : 1 ) cardiac steatosis play pivotal role early pathogenesis obesity-related adverse cardiac remodeling human , 2 ) Nebivolol improve cardiac remodel via unique metabolic ability reduce cardiac steatosis beyond effect hemodynamic cardiac remodel due blood pressure reduction . Study Design Hypotheses : Before six month low dose ( 10 mg daily ) Nebivolol treatment , localize proton MR spectroscopy ( measure triglyceride content myocytes , well liver , pancreas skeletal muscle ) cardiac MRI ( structural functional measurement leave ventricle ) perform . Additionally , study abdominal subcutaneous fat level six month period ( MRI Bioimpedance ) .</detailed_description>
	<mesh_term>Fatty Liver</mesh_term>
	<mesh_term>Nebivolol</mesh_term>
	<criteria>Mexican American men woman Age 18 59 Metabolic Syndrome* Myocardial TG &gt; = 0.5 % localized MR spectroscopy *Metabolic syndrome study follow NCEP ATP III ( National Cholesterol Education Program Adult Treatment Panel III ) Guidelines include &gt; = 3 follow : Fasting blood glucose &gt; = 100 mg/dL Waist circumference : Men &gt; 102 cm , Women &gt; 88 cm Triglycerides &gt; = 150 mg/dL BP &gt; 130/85 Current use betablocker HR &lt; 50 beats/min BP &lt; 130/85 Contraindication betablocker therapy asthma , reactive airway disease , heart block , depression CHF ( NYHA class ) history , physical examination , current use CHF medication include betablockers , ACE inhibitor , angiotensin receptor blocker ( ARBs ) , diuretic , calcium channel blocker , digitoxin , hydralazine , nitrate ( include sublingual nitroglycerin ) , inotropic agent LVEF &lt; 50 % cardiac MRI Hepatic insufficiency current use another medication also metabolize CYP2D6 isozyme ( paroxetine , fluoxetine , quinidine , propafenone ) . Any contraindication MRI , e.g . metallic implant , metallic tattoo , claustrophobia , weight &gt; 350 pound ( MRI weight limit ) Pregnancy time study A recent weight loss ( &gt; 10 % body weight within past year ) plan undergo significant weight reduction ( &gt; 10 % body weight ) experimental protocol .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>59 Years</maximum_age>
	<verification_date>May 2011</verification_date>
	<keyword>steatosis</keyword>
	<keyword>MR spectroscopy</keyword>
	<keyword>Nebivolol</keyword>
	<keyword>cardiac MRI</keyword>
</DOC>